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AbstrACt
Objectives The aim of this study was to identify, with 
soft clustering methods, multimorbidity patterns in the 
electronic health records of a population ≥65 years, 
and to analyse such patterns in accordance with the 
different prevalence cut-off points applied. Fuzzy cluster 
analysis allows individuals to be linked simultaneously 
to multiple clusters and is more consistent with clinical 
experience than other approaches frequently found in 
the literature.
Design A cross-sectional study was conducted based on 
data from electronic health records.
setting 284 primary healthcare centres in Catalonia, 
Spain (2012).
Participants 916 619 eligible individuals were included 
(women: 57.7%).
Primary and secondary outcome measures We 
extracted data on demographics, International 
Classification of Diseases version 10 chronic diagnoses, 
prescribed drugs and socioeconomic status for patients 
aged ≥65. Following principal component analysis of 
categorical and continuous variables for dimensionality 
reduction, machine learning techniques were applied for 
the identification of disease clusters in a fuzzy c-means 
analysis. Sensitivity analyses, with different prevalence 
cut-off points for chronic diseases, were also conducted. 
Solutions were evaluated from clinical consistency and 
significance criteria.
results Multimorbidity was present in 93.1%. Eight 
clusters were identified with a varying number of disease 
values: nervous and digestive; respiratory, circulatory and 
nervous; circulatory and digestive; mental, nervous and 
digestive, female dominant; mental, digestive and blood, 
female oldest-old dominant; nervous, musculoskeletal 
and circulatory, female dominant; genitourinary, mental 
and musculoskeletal, male dominant; and non-specified, 
youngest-old dominant. Nuclear diseases were identified 
for each cluster independently of the prevalence cut-off 
point considered.
Conclusions Multimorbidity patterns were obtained 
using fuzzy c-means cluster analysis. They are clinically 
meaningful clusters which support the development of 
tailored approaches to multimorbidity management and 
further research.
IntrODuCtIOn
The term multimorbidity widely refers to the 
existence of numerous medical conditions in 
a single individual.1 In many regions of the 
world there is evidence that a substantial, and 
probably growing, proportion of the adult 
population is affected by multiple chronic 
conditions. Moreover, the association of 
multimorbidity with increasing age leading 
to a two-fold prevalence in the final decades 
of life has been proven.2 Multimorbidity has 
strengths and limitations of this study
 ► Studies focus on diseases rather than individuals 
as the unit of analysis in assessing multimorbidity 
patterns (hard clustering forces each individual to 
belong to a single cluster, whereas soft clustering 
allows elements to be simultaneously classified into 
multiple cluster).
 ► Reliable and valid identification of disease clusters 
is needed for the development of evidence-based 
clinical practice guidelines and pathways of care 
for patients that correspond to the wide spectrum of 
diseases in patients with multimorbidity.
 ► Soft clustering analysis allows for diseases to be 
linked simultaneously to multiple clusters and is 
more consistent with clinical experience than other 
approaches frequently found in the literature.
 ► The different cut-off points (prevalence filters) ap-
plied to obtain multimorbidity patterns permitted the 
identification of common nuclear diseases which 
remained independent of their prevalence.
 ► The literature provides support for the aetiopatho-
physiological and epidemiological associations be-
tween conditions forming part of the same cluster.
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been estimated to be at around 62% between 65 and 74 
years, and around 81.5% after 85 years.3 Its true extent is, 
however, difficult to gauge as there is no agreed defini-
tion or classification system.4–7
Most of the published literature focuses on diseases 
rather than individuals as the unit of analysis in assessing 
multimorbidity patterns.8 Orienting the analysis of 
multimorbidity patterns at an individual level, and not 
of disease, could have crucial implications for patients. 
In the current context of limited evidence on interven-
tions for unselected patients with multimorbidity, such an 
approach–would allow better understanding of popula-
tion groups, and facilitate the development and imple-
mentation of strategies aimed at prevention, diagnosis, 
treatment and prognosis. It would also elicit essential 
information for the development of clinical guidelines, 
pathways of care, and lead to better understanding of the 
nature and range of the required health services.9 10
Cluster analysis involves assigning individuals so that 
the items (diseases) in the same cluster are as similar as 
possible, while individuals belonging to different clusters 
are as dissimilar as possible. The identification of clus-
ters is based on similarity measures and their choice may 
depend on the data or the purpose of the analysis.11 12 
Hard clustering forces each element to belong to a single 
cluster, whereas soft clustering (also referred to as fuzzy 
clustering) allows elements to be simultaneously classi-
fied into multiple clusters.
Empirical evidence is needed on how both estab-
lished and novel techniques influence the identification 
of multimorbidity patterns. A recent systematic review 
recommended that future epidemiological studies 
cover a broad selection of health conditions in order 
to avoid missing potentially key nosological associations 
and enhance external validity. When many conditions 
are considered, the clustering of individuals based on 
morbidity data will encounter high-dimensional issues. 
This is particularly important when a clustering-based 
approach is adopted to assess the impact of multimor-
bidity on individual health outcomes and health service 
uses.2 8 13–15
The identification of multimorbidity patterns seems to 
be implicitly dependent on the prevalence of the included 
diseases.2 8 16 17 However, to the best of our knowledge no 
previous study has analysed the identification of multi-
morbidity patterns explicitly based on the prevalence of 
the diseases.
The aim of this study was to identify, with soft clus-
tering methods, multimorbidity patterns in the electronic 
health records of a population ≥65 years, and to analyse 
such patterns in accordance with the different prevalence 
cut-off points applied.
MethODs
study population
A cross-sectional analysis was carried out in Catalonia 
(Spain), a Mediterranean region of 7 515 398 inhabitants 
(2012). The Catalan Health Institute provides universal 
coverage and operates 284 primary healthcare centres 
(PHC).
Data sources
Since 2006 the Information System for Research in 
Primary Care (SIDIAP) database includes anonymised 
longitudinal electronic health records from primary 
and secondary care which gather information on demo-
graphics, diagnoses, prescriptions and socioeconomic 
status.18 In our study the inclusion criteria were individ-
uals aged 65–99 years on 31 December 2011 with at least 
one PHC visit since 2012. Only participants who survived 
until 31 December 2012 (index date) were included in 
the analysis.
Variables
Diseases were coded in the SIDIAP using the Interna-
tional Classification of Diseases version 10. An opera-
tional definition of multimorbidity was the simultaneous 
presence of more than one of the selected 60 chronic 
diseases previously identified by the Swedish National 
study of Aging and Care in Kungsholmen (SNAC-K).19
Additional variables included in the study were socio-
demographics (age, sex, socioeconomic status (MEDEA 
index20)), clinical variables (including number of chronic 
diseases and invoiced drugs) and use of health services 
(number of visits to family physicians, nurses and emer-
gency services).
statistical analysis
Descriptive statistics were used to summarise overall 
information. Disease prevalence was computed for all 
the included population. Descriptive analyses were strat-
ified by the presence of multimorbidity. Comparison was 
performed using Student’s t-test or Mann-Whitney test 
for continuous variables and χ2 test for categorical ones.
In order to obtain the most representative clusters 
all patients were included irrespective of whether they 
presented multimorbidity or not. Sex and age variables, 
together with chronic diseases selected by prevalence, 
were included in the analysis. The number of features to 
be considered varied from the 62 original ones (no prev-
alence filtering applied) to 54 and 49, for a 1% and 2% 
prevalence threshold, respectively.
Due to the large number of diseases, a principal 
component analysis for categorical and continuous data 
(PCAmix) was implemented to reduce complexity. With 
this technique both continuous and dichotomous vari-
ables were simultaneously processed through the appli-
cation of Multiple Correspondence Analysis to the binary 
variables and PCA to the continuous ones. Using Karl-
is-Saporta-Spinaki criterion to select the optimal number 
of dimensions to retain, the data set of 49 features per 
individual per 2% prevalence cut-off was transformed to 
a new dimensionally reduced data set of 13 continuous 
features per individual, which concentrated most of the 
variability of the newly transformed data set.21
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Figure 1 Study population flow chart. *See 60 chronic 
diseases group defined in Swedish National study of Aging 
and Care in Kungsholmen (SNAC-K).25
Once the transformed data set was obtained, clusters 
of chronic conditions at baseline were identified using 
the fuzzy c-means clustering algorithm.22 This Machine 
learning technique forces every individual to belong to 
every cluster in accordance with its characteristics and by 
assigning a membership degree factor in (0, 1) to each 
individual with respect to each pattern. This provides the 
flexibility enabling patients to belong to more than one 
multimorbidity pattern.23
The main parameters in this clustering procedure were 
the number of clusters and a fuzziness parameter, denoted 
m, which ranged from just above 1 to infinity. High m 
values produce a fuzzy set of clusters, so that individuals 
are equally distributed across clusters, whereas lower ones 
generate non-overlapped clusters. Further details on the 
stability and validation techniques applied to obtain the 
best fuzzy c-means parameters and the set of centroids are 
presented in online supplementary additional file 1.
To describe the multimorbidity patterns, frequencies 
and percentages of diseases (P) in each cluster were 
calculated. Observed/expected ratios (O/E ratios) were 
calculated by dividing disease prevalence in the cluster 
by disease prevalence in the overall population. As the 
membership of each individual to any of the clusters was 
given by a membership degree factor, and not as a binary 
variable, the observed disease prevalence (O) in a cluster 
was computed as the sum of the disease membership 
degree factors corresponding to all individuals suffering 
the disease. Exclusivity, defined as the proportion of 
patients with the disease included in the cluster over the 
total number of patients with the disease, was also calcu-
lated. Further details on how these ratios were computed 
using the membership factors are given in online supple-
mentary additional file 1. A disease was considered 
to be part of a multimorbidity cluster when O/E ratio 
was ≥2 or exclusivity value ≥25%.24 Clusters names were 
also defined taking into account the dominant gender 
or age in the cluster compared with the overall sample 
distribution.
We conducted a sensitivity analysis by modifying the 
prevalence threshold for disease inclusion in the cluster 
analysis. For chronic diseases we considered as alterna-
tives no filtering, and ≥1% and ≥2% filters among the 
included population. In order to conform to the Karl-
is-Saporta-Spinaki rule, a different number of dimensions 
of the transformed data set were retained to construct the 
clusters for every prevalence cut-off: 13 dimensions for 
the 2% prevalence, 14 dimensions for the 1% prevalence 
and 17 dimensions with no filtering. The content of each 
cluster was compared across filtering approaches in terms 
of diseases associated with that cluster, characteristics of 
the included population and cluster size. Clinical evalua-
tion of the consistency and significance of these solutions 
was also conducted.
The analyses were carried out using R V.3.3.1 (R Foun-
dation for Statistical Computing, Vienna, Austria). The 
significance level was set at 0.05.
Patient and public involvement
Patients were not involved in the study based on anony-
mised data.
results
In this study, 916 619 individuals were included (women: 
57.7%; mean age: 75.4 (SD: 7.4)), and 853 085 (93.1%) of 
them met multimorbidity criteria (figure 1).
Participants’ characteristics are summarised in table 1. 
Statistically significant differences were present between 
the multimorbidity and non-multimorbidity groups for 
all the variables included in the analysis (table 1).
Among the 60 SNAC-K chronic diseases, the most 
prevalent were: hypertension (71.0%), dyslipidaemia 
(50.9%), osteoarthritis and other degenerative joint 
diseases (32.8%), obesity (28.7%), diabetes (25.1%) and 
anaemia (18.3%) (table 2).
Eight multimorbidity patterns were identified using 
fuzzy c-means algorithm with fuzziness parameter of 
m=1.1, after computing different validation indices to 
obtain the optimal number of clusters (online supple-
mentary additional file 1). This number was the same for 
the three different prevalence thresholds: no filtering, 
and ≥1% and ≥2% filters. The cluster formed by the most 
prevalent diseases was designated non-specified, young-
est-old dominant (O/E ratio <2 and exclusivity <20). The 
remaining seven clusters were specific: nervous and diges-
tive; respiratory, circulatory and nervous; circulatory and diges-
tive; mental, nervous and digestive, female dominant; mental, 
digestive and blood, female oldest-old dominant; nervous, 
musculoskeletal and circulatory, female dominant; and genito-
urinary, mental and musculoskeletal, male dominant (table 3). 
Table 3 shows the results, considering a 2% prevalence 
filter, for each pattern based on the 15 diseases with the 
higher O/E ratios.
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Table 1 Characteristics of study participants aged 65–94 years stratified by multimorbidity and non-multimorbidity 
(n=916 619, Catalonia, 2012)
Variables*
Multimorbidity
(n=853 085)
Non-multimorbidity
(n=63 534)
All
(n=916 619)
Sex, women, n (%) 496 294 (58.2) 32 837 (51.7) 529 131 (57.7)
Age, mean (SD) 75.6 (7.4) 73.2 (7.3) 75.4 (7.4)
Age (categories), n (%)
  (65, 70) 225 514 (26.4) 26 664 (42.0) 252 178 (27.5)
  (70, 80) 370 356 (43.4) 24 230 (38.1) 394 586 (43.0)
  (80, 90) 224 143 (26.3) 10 601 (16.7) 234 744 (25.6)
  ≥90 33 072 (3.9) 2039 (3.2) 35 111 (3.8)
MEDEA index†
  Q1 130 894 (16.5) 13 897 (23.4) 144 791 (17.0)
  Q2 126 537 (16.0) 9894 (16.6) 136 431 (16.0)
  Q3 129 246 (16.3) 8976 (15.1) 138 222 (16.2)
  Q4 125 322 (15.8) 7666 (12.9) 132 988 (15.6)
  Q5 110 916 (14.0) 5967 (10.0) 116 883 (13.7)
  Rural 169 190 (21.4) 13 059 (22.0) 182 249 (21.4)
Number of chronic diseases, median (IQR) 6.0 (4.0; 8.0) 1.0 (0.0; 1.0) 6.0 (4.0; 8.0)
Number of chronic diseases (categories), n (%)
  0 0 (0.0) 25 380 (39.9) 25 380 (2.8)
  1 0 (0.0) 38 154 (60.1) 38 154 (4.2)
  (2, 5) 268 836 (31.5) 0 (0.0) 268 836 (29.3)
  (5, 10) 463 709 (54.4) 0 (0.0) 463 709 (50.6)
  ≥10 120 540 (14.1) 0 (0.0) 120 540 (13.2)
Number of drugs, median (IQR) 5.0 (3.0; 8.0) 0.0 (0.0; 1.0) 5.0 (2.0; 8.0)
Number of drugs (categories)
  0 72 557 (8.5) 40 811 (64.2) 113 368 (12.4)
  1 48 704 (5.7) 8378 (13.2) 57 082 (6.2)
  (2, 5) 247 095 (29.0) 11 572 (18.2) 258 667 (28.2)
  (5, 10) 360 030 (42.2) 2651 (4.2) 362 681 (39.6)
  ≥10 124 699 (14.6) 122 (0.2) 124 821 (13.6)
Number of visits, median (IQR) 10.0 (6.0; 17.0) 1.0 (0.0; 4.0) 9.0 (5.0; 16.0)
Number of visits 2012 (categories), n (%)
  0 24 543 (2.9) 23 402 (36.8) 47 945 (5.2)
  1 24 281 (2.8) 9603 (15.1) 33 884 (3.7)
  (2, 5) 114 198 (13.4) 16 241 (25.6) 130 439 (14.2)
  (5, 10) 239 181 (28.0) 10 168 (16.0) 249 349 (27.2)
  ≥10 450 882 (52.9) 4120 (6.5) 455 002 (49.6)
*All comparisons between variables in multimorbidity and non-multimorbidity showed p<0.001.
†MEDEA index goes from 1 (least deprived) to 5 (most deprived), in this variable n=851 564.
Women were more represented than men in almost all 
clusters, from 52.7% for respiratory, circulatory and neuro-
logical to 83.6% for mental, nervous and digestive, female 
dominant. The exception was genitourinary, mental and 
musculoskeletal, male dominant in which men made up 
90.9% due to the presence of male reproductive system 
diseases (table 4).
The highest O/E ratio and exclusivity value were 
observed in nervous and digestive for Parkinson, parkin-
sonism and other neurological diseases (17.0% and 
74.3%, and 15.9% and 69.4%, respectively). The lowest 
values were found in non-specified, youngest-old dominant. 
Clusters 1–3 presented the highest median number of 
visits with circulatory and digestive being associated with the 
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Table 2 Prevalence of the 60 chronic diseases included in the study in individuals aged 65–94 years (n=916 619, Catalonia, 
2012)
Rank Chronic conditions Frequency Percentage (%)
All diseases 
included 1% 2%
1 Hypertension 650 899 71
2 Dyslipidaemia 466 585 50.9
3 Osteoarthritis and other degenerative joint diseases 300 803 32.8
4 Obesity 262 888 28.7
5 Diabetes 230 460 25.1
6 Anaemia 167 577 18.3
7 Cataract and other lens diseases 156 622 17.1
8 Chronic kidney diseases 153 756 16.8
9 Prostate diseases 153 635 16.8
10 Osteoporosis 151 847 16.6
11 Depression and mood diseases 148 751 16.2
12 Solid neoplasms 137 045 15
13 Colitis and related diseases 131 512 14.4
14 Venous and lymphatic diseases 126 997 13.9
15 Other musculoskeletal and joint diseases 124 765 13.6
16 Dorsopathies 124 603 13.6
17 Neurotic, stress-related and somatoform diseases 123 395 13.5
18 COPD, emphysema, chronic bronchitis 109 603 12
19 Ischaemic heart disease 95 434 10.4
20 Deafness, hearing impairment 90 261 9.9
21 Sleep disorders 88 739 9.7
22 Thyroid diseases 88 445 9.7
23 Other genitourinary diseases 85 468 9.3
24 Cerebrovascular disease 80 264 8.8
25 Atrial fibrillation 80 247 8.8
26 Oesophagus, stomach and duodenum diseases 80 043 8.7
27 Heart failure 74 077 8.1
28 Other eye diseases 68 939 7.5
29 Glaucoma 66 162 7.2
30 Inflammatory arthropathies 62 450 6.8
31 Dementia 59 213 6.5
32 Cardiac valve diseases 52 100 5.7
33 Peripheral neuropathy 49 127 5.4
34 Other psychiatric and behavioural diseases 46 841 5.1
35 Asthma 43 663 4.8
36 Allergy 40 394 4.4
37 Autoimmune diseases 39 350 4.3
38 Ear, nose, throat diseases 38 752 4.2
39 Peripheral vascular disease 30 674 3.4
40 Other neurological diseases 28 541 3.1
41 Chronic pancreas, biliary tract and gall bladder 
diseases
27 321 3
42 Migraine and facial pain syndromes 25 999 2.8
43 Bradycardias and conduction diseases 25 476 2.8
44 Chronic liver diseases 22 633 2.5
Continued
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Rank Chronic conditions Frequency Percentage (%)
All diseases 
included 1% 2%
45 Other digestive diseases 22 022 2.4
46 Parkinson and parkinsonism 20 833 2.3
47 Other metabolic diseases 18 997 2.1
48 Other cardiovascular diseases 16 833 1.8
49 Other skin diseases 15 363 1.7
50 Chronic ulcer of the skin 13 869 1.5
51 Blood and blood-forming organ diseases 13 575 1.5
52 Other respiratory diseases 9974 1.1
53 Epilepsy 8981 1
54 Haematological neoplasms 8174 0.9
55 Chronic infectious diseases 6647 0.7
56 Inflammatory bowel diseases 5549 0.6
57 Schizophrenia and delusional diseases 4792 0.5
58 Blindness, visual impairment 4772 0.5
59 Multiple sclerosis 576 0.1
60 Chromosomal abnormalities 77 0
In the last three columns, list of diseases was included by prevalence cut-off (All, 1%, 2%).
COPD, chronic obstructive pulmonary disease.
Table 2 Continued
greatest number of visits over a 1 year period (median 18 
visits), and the non-specified, youngest-old dominant pattern 
presenting the lowest median number of visits which was 
equal to 5 (table 4). Online supplementary additional file 
2 shows tables of variables characterising each cluster in 
baseline study for 1% and for no prevalence cut-off points.
Multimorbidity patterns varied according to require-
ments for minimal prevalence of selected conditions 
in the population. As an example, figure 2 depicts the 
composition of cluster 1 according to prevalence levels of 
disease, and the other clusters are shown in online supple-
mentary additional file 3. Disease prevalence varied more 
greatly in the less populated patterns (eg, non-specified, 
youngest-old dominant) (online supplementary additional 
file 3). Nevertheless, there was a group that remained in 
some clusters across all prevalence levels, for instance, 
some in neurological and digestive (Parkinson and parkin-
sonism, other neurological diseases, chronic liver diseases, 
chronic pancreas, biliary tract and gall bladder diseases) 
formed part of the cluster regardless of changes in cut-off 
prevalence (online supplementary additional file 3). The 
selected level of prevalence resulted in changes in O/E 
ratios, with some of them doubling their values.
DIsCussIOn
The soft clustering method we employed identified eight 
multimorbidity patterns, regardless of the prevalence 
selected. The non-specified, youngest-old dominant cluster 
included the largest number of individuals and those 
who presented the smallest multimorbidity prevalence. 
In this pattern diseases did not exhibit an association 
higher than chance because values of the O/E ratio and 
exclusivity were less than 2% and 20%, respectively. This 
suggests that such patients during their lives could change 
group. Two clusters presenting gender dominance were 
observed: nervous, musculoskeletal and circulatory, female 
dominant was predominately made up of women >70 
years, while genitourinary, mental and musculoskeletal, male 
dominant was mostly formed of men of the same age. 
Such patterns represent 61% of the elderly participants 
included in the study. The rest had fewer individuals and 
some diseases were over-represented such as Parkinson 
and parkinsonism in nervous and digestive, and asthma in 
respiratory, circulatory and nervous.
We observed that some diseases with O/E ratios ≥2 
were consistently associated with each other as part of 
the same clusters (for instance, nervous and digestive; respi-
ratory, circulatory and nervous; circulatory and digestive; and 
mental, nervous and digestive, female dominant) regardless of 
the prevalence threshold that had been set. They can be 
considered core components of those clusters. Further 
research is needed to establish the role of these condi-
tions from a longitudinal perspective.
Comparison with the literature
Comparison with other studies is hindered by variations 
in methods, data sources and structures, populations and 
diseases studied. Nevertheless, there are similarities with 
other authors. The non-specified pattern is the one most 
replicated in the literature, for example, Prados-Torres et 
al who employed an exploratory factor analysis25 and our 
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Table 3 Most frequent 15 diseases found in multimorbidity patterns in individuals aged 65–94 years (n=916 619, Catalonia, 
2012)
Pattern Disease O
O/E 
ratio EX Pattern Disease O
O/E 
ratio EX
1
Nervous and digestive
(n=40 037)
Parkinson and 
parkinsonism
38.7 17 74.3 2
Respiratory, circulatory and 
nervous
(n=50 639)
Asthma 34.5 7.2 40
Other neurological 
diseases
49.5 15.9 69.4 Peripheral vascular 
disease
13.9 4.2 22.9
Chronic liver diseases 13.2 5.4 23.4 Parkinson and 
parkinsonism
8.5 3.8 20.8
Chronic pancreas, 
biliary tract and gall 
bladder diseases
7.9 2.7 11.6 Other neurological 
diseases
11.7 3.7 20.7
Dementia 14.7 2.3 9.9 COPD, emphysema, 
chronic bronchitis
31 2.6 14.3
Other digestive 
diseases
4.8 2 8.7 Allergy 10.8 2.4 13.5
Cerebrovascular 
disease
16.9 1.9 8.4 Heart failure 16.6 2 11.3
Colitis and related 
diseases
24.1 1.7 7.3 Ischaemic heart 
disease
21.1 2 11.2
Other metabolic 
diseases
3.4 1.7 7.2 Other eye diseases 14 1.9 10.3
Depression and mood 
diseases
25 1.5 6.7 Autoimmune diseases 7.2 1.7 9.3
Anaemia 26.1 1.4 6.2 Other psychiatric and 
behavioural diseases
8.5 1.7 9.2
Oesophagus, 
stomach and 
duodenum diseases
11.3 1.3 5.6 Ear, nose, throat 
diseases
7.1 1.7 9.2
Sleep disorders 12.4 1.3 5.6 Anaemia 30.4 1.7 9.2
Other eye diseases 9.6 1.3 5.6 Peripheral neuropathy 8.8 1.6 9.1
Dorsopathies 17 1.2 5.4 Cerebrovascular 
disease
14.3 1.6 9
3
Circulatory and 
digestive
(n=67 492)
Heart failure 51.4 6.4 46.9 4
Mental, nervous and 
digestive, female dominant
(n=94 453)
Neurotic, stress-
related and 
somatoform diseases
64.9 4.8 49.7
Cardiac valve 
diseases
34.2 6 44.3 Depression and mood 
diseases
66.4 4.1 42.1
Atrial fibrillation 47.3 5.4 39.8 Migraine and facial 
pain syndromes
8.2 2.9 29.6
Bradycardias and 
conduction diseases
13.5 4.9 35.9 Sleep disorders 19 2 20.2
Ischaemic heart 
disease
33.7 3.2 23.8 Oesophagus, 
stomach and 
duodenum diseases
14.9 1.7 17.6
Chronic pancreas, 
biliary tract and gall 
bladder diseases
8 2.7 19.7 Osteoporosis 28 1.7 17.4
Chronic liver diseases 6.1 2.5 18.2 Thyroid diseases 16 1.7 17.1
Chronic kidney 
diseases
35.9 2.1 15.8 Colitis and related 
diseases
23.7 1.7 17
Anaemia 38.6 2.1 15.5 Other genitourinary 
diseases
14.4 1.5 15.9
Cerebrovascular 
disease
18.3 2.1 15.4 Ear, nose, throat 
diseases
6.2 1.5 15.2
COPD, emphysema, 
chronic bronchitis
23.6 2 14.5 Venous and lymphatic 
diseases
19.9 1.4 14.8
Other digestive 
diseases
4.6 1.9 14 Allergy 6.1 1.4 14.3
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Pattern Disease O
O/E 
ratio EX Pattern Disease O
O/E 
ratio EX
Peripheral vascular 
disease
6.1 1.8 13.3 Osteoarthritis and 
other degenerative 
joint diseases
45 1.4 14.1
Other metabolic 
diseases
3.2 1.5 11.3 Dorsopathies 18 1.3 13.7
Dementia 9.5 1.5 10.9 Cardiac valve 
diseases
7.4 1.3 13.5
5
Mental, digestive and 
blood, female oldest-
old dominant
(n=106 845)
Dementia 21.8 3.4 39.4 6
Nervous, musculoskeletal 
and circulatory, female 
dominant
(n=145 074)
Peripheral neuropathy 12.4 2.3 36.6
Other digestive 
diseases
5.8 2.4 28.1 Other musculoskeletal 
and joint diseases
26 1.9 30.2
Anaemia 38.5 2.1 24.6 Venous and lymphatic 
diseases
26.4 1.9 30.2
Chronic kidney 
diseases
33.3 2 23.1 Dorsopathies 25.3 1.9 29.4
Colitis and related 
diseases
26.2 1.8 21.3 Obesity 51 1.8 28.2
Cerebrovascular 
disease
14.8 1.7 19.7 Other genitourinary 
diseases
16 1.7 27.2
Osteoporosis 26 1.6 18.3 Osteoarthritis and 
other degenerative 
joint diseases
55 1.7 26.5
Cataract and other 
lens diseases
25.9 1.5 17.7 Osteoporosis 24.8 1.5 23.7
Deafness, hearing 
impairment
14 1.4 16.5 Other eye diseases 10.7 1.4 22.4
Venous and lymphatic 
diseases
19.5 1.4 16.4 Cataract and other 
lens diseases
22.5 1.3 20.8
Osteoarthritis and 
other degenerative 
joint diseases
45.5 1.4 16.2 Thyroid diseases 12.6 1.3 20.7
Depression and mood 
diseases
22.5 1.4 16.1 Glaucoma 9.2 1.3 20.1
Other genitourinary 
diseases
12.3 1.3 15.4 Diabetes 31.3 1.2 19.7
Other eye diseases 9.9 1.3 15.4 Ear, nose, throat 
diseases
5.2 1.2 19.5
Sleep disorders 12.4 1.3 14.9 Dyslipidaemia 62.7 1.2 19.5
7
Genitourinary, mental 
and musculoskeletal, 
male dominant
(n=173 746)
Prostate diseases 54.7 3.3 61.8 8
Non-specified, youngest-
old dominant
(n=238 333)
Dyslipidaemia 38.4 0.8 19.6
Other psychiatric and 
behavioural diseases
11.1 2.2 41.2 Thyroid diseases 7.3 0.8 19.6
Inflammatory 
arthropathies
12.4 1.8 34.5 Osteoporosis 12.2 0.7 19.2
COPD, emphysema, 
chronic bronchitis
20.5 1.7 32.5 Hypertension 47.6 0.7 17.4
Solid neoplasms 21.8 1.5 27.7 Glaucoma 4.4 0.6 16
Peripheral vascular 
disease
4.7 1.4 26.7 Solid neoplasms 9.1 0.6 15.7
Ischaemic heart 
disease
13.7 1.3 25 Migraine and facial 
pain syndromes
1.7 0.6 15.7
Diabetes 31.8 1.3 24 Autoimmune
diseases
2.2 0.5 13.4
Ear, nose, throat 
diseases
5.3 1.3 23.7 Other metabolic 
diseases
1.1 0.5 13.3
Deafness, hearing 
impairment
11.6 1.2 22.3 Allergy 2.2 0.5 13
Allergy 4.8 1.1 20.5 Chronic liver diseases 1.2 0.5 12.8
Table 3 Continued
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Pattern Disease O
O/E 
ratio EX Pattern Disease O
O/E 
ratio EX
Hypertension 75.8 1.1 20.2 Other genitourinary 
diseases
4.5 0.5 12.7
Glaucoma 7.5 1 19.6 Oesophagus, 
stomach and 
duodenum diseases
4.1 0.5 12.2
Autoimmune diseases 4.4 1 19.4 Other psychiatric and 
behavioural diseases
2.4 0.5 12
Obesity 29 1 19.2 Diabetes 10.8 0.4 11.2
COPD, chronic obstructive pulmonary disease; EX, exclusivity; O, disease prevalence in the cluster; O/E ratio, observed/expected ratio.
Table 3 Continued
group with k-means.24 Specifically, although the age range 
and the exclusivity threshold in our previous study were 
different, the hard clustering method provided clusters 
that overlap with some of the patterns obtained in this 
study, since both clustering results were predominantly 
defined by the O/E ratio (≥2) criteria. However, the soft 
approach allows a more flexible distribution of the indi-
vidual and diseases.
Recent research has provided support for physiopatho-
logical and genetic associations that explain the observed 
multimorbidity patterns. For instance, neurological and 
digestive included chronic liver disease which has been 
linked to Parkinson through the accumulation of toxic 
substances in the brain (ammonia and manganese) 
and neuroinflammation.26 A higher risk of Parkinson 
among patients with chronic hepatitis C virus has also 
been reported (OR: 1.35),27 in addition to associations 
between digestive diseases and neurodegenerative ones 
(eg, Parkinson and Alzheimer) through the microbi-
ome-gut-brain axis.27 A possible link between micro-
biota and digestive diseases such as chronic pancreatitis 
and pancreatic cancer has also been suggested.28 29 For 
the respiratory, circulatory and neurological cluster there is 
evidence of an association between chronic bronchial 
pathology, particularly asthma and chronic obstructive 
pulmonary disease (COPD), and the risk of cardiovas-
cular events.30 Longitudinal studies have observed an 
increased risk of developing Parkinson among individuals 
suffering from asthma and/or COPD.31 32 The association 
between asthma and allergy is known, and its coexis-
tence defines a specific phenotype. For the circulatory and 
digestive cluster, non-alcoholic fatty liver disease has been 
associated with the development of atrial fibrillation,33 
and hepatitis C infection with an increase in the risk of 
developing cardiovascular and cerebrovascular events.34 
In addition, anaemia has been associated with advanced 
stages of chronic renal diseases and erythropoietin defi-
ciency.35 Iron deficiency anaemia has been associated 
with an increased risk of stroke36 through thromboem-
bolic phenomena secondary to reactive thrombocytosis. 
Chronic kidney disease produces auricle injuries (dila-
tation, fibrosis) and systemic inflammation, both of 
which can favour the onset and maintenance of atrial 
fibrillation.37
strengths and limitations
A major strength of this study is that it has employed a 
large, high-quality database made up of primary care 
records representative of the Catalan population aged ≥65 
years.18 Patterns of multimorbidity have been studied 
based on the whole eligible sample. This approach is 
epidemiologically robust as the prevalence of diseases has 
been estimated on the whole sample rather than limited 
to patients with multimorbidity.2 Another strength is that 
individuals rather than diseases have been considered as 
the unit of analysis.8 24 Such an approach permits a more 
realistic and rational monitoring of participants than 
cohort studies in order to analyse multimorbidity patterns 
along time. Moreover, the use of different prevalence 
cut-offs to obtain multimorbidity patterns has allowed the 
identification of nuclear diseases. We selected the higher 
prevalence (2%) because the patterns obtained had more 
clinical representativeness. The inclusion of all the poten-
tial diagnoses may have signified a greater complexity that 
would have hindered both the interpretation of findings 
and comparison with other studies.
Compared with hierarchical clustering, fuzzy c-means 
cluster analysis is less susceptible to: outliers in the data, 
choice of distance measure and the inclusion of inappro-
priate or irrelevant variables.38 Nevertheless, some disad-
vantages of the method are that different solutions for 
each set of seed points can occur and there is no guarantee 
of optimal clustering.11 To minimise this shortcoming, we 
carried out 100 cluster realisations with different seeds 
to finally use the average result of all of them. In addi-
tion, the method is not efficient when a large number 
of potential cluster solutions are to be considered.38 To 
address this limitation, we computed the optimal number 
of clusters using analytical indexes (online supplemen-
tary additional file 1).
Other limitations need to be taken into account. The 
dimensional reduction method performed in this work to 
reduce data complexity was PCAmix. Such methods can 
produce low percentages of variation on principal axes 
and make it difficult to choose the number of dimensions 
to retain. In order to decide on the most suitable number 
of dimensions we applied the Karlis-Saporta-Spinaki rule27 
which resulted in a 13-dimensional space for the 2% prev-
alence cut-off. Furthermore, the feasibility of developing 
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Figure 2 Composition of cluster 1 (nervous and digestive) in individuals aged 65–94 years according to disease levels of 
prevalence (n=916 619, Catalonia, 2012). COPD, chronic obstructive pulmonary disease; O/E ratio, observed/expected ratio.
clinical practice guidelines in accordance with these 
patterns might prove difficult due to the dimension of 
the diseases included in each pattern. Nonetheless, new 
clinical practice guidelines should consider the diseases 
that are over-represented (O/E ratio ≥2).
Implications for practice, policy and research
Soft clustering methods offer a new methodological 
approach to understanding the relationships between 
specific diseases in individuals. This is an essential step 
in improving the care of patients and health systems. 
Analysing multimorbidity patterns permits the identi-
fication of patient subgroups with different associated 
diseases. Our analysis focuses on groups of patients as 
opposed to diseases. In this case, a disease is present 
in all patterns (clusters), but in different degrees. In 
this context, the O/E ratios are used to measure which 
diseases are over-represented in each cluster and to lead 
the clinical practice guidelines. The inclusion of varying 
cut-off points (prevalence filters) of the diseases that 
form the multimorbidity patterns allowed us to identify 
common nuclear diseases that remained independent 
from the prevalence that build such patterns.
It is noteworthy that 60% of the population ≥65 years 
was included in multimorbidity patterns made up of the 
most prevalent diseases. The rest of the population was 
grouped into five more specific patterns which permitted 
their better management.
While clinical guidelines are currently aimed at 
covering the management of the diseases found in the 
non-specified, youngest-old dominant cluster, there is a lack 
of information regarding the associated diseases in the 
other patterns. The challenge will be to refocus health-
care policy from that based on individual diseases, with 
the accompanying consequences (increased risk of 
functional decline, poorer quality of life, greater use of 
services, polypharmacy and increased mortality), to a 
multimorbidity orientation.39
Further investigation on this topic is called for with 
particular focus on five major issues. First, the genetic 
study of these patterns will help the identification of risk 
subgroups. Second, research is needed on the life style 
and environmental factors (diet, physical exercise, toxics) 
associated with such patterns. Third, longitudinal studies 
should be performed to establish the onset order of the 
core diseases. Fourth, alternative approaches to handle 
covariates in cluster analysis should be addressed in future 
analysis plan. Recently, a new method that allows the 
covariates to be incorporated into the membership factor 
to model individual probabilities of cluster membership 
has been proposed.40 And fifth, the characteristics of the 
diseases in the same cluster and their potential implica-
tion on the quality of primary care should be ascertained 
in greater detail.
Our findings suggest non-hierarchical cluster analysis 
identified multimorbidity patterns and phenotypes of 
certain subgroups of patients that were more consistent 
with clinical practice.
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Additional File 1 
A) Extracting and Validating Multimorbidity Patterns by applying the Fuzzy C Means 
Clustering algorithm. 
In this annex we present a description of the procedure followed to obtain a set of multimorbidity 
patterns characterizing a patient population aged 65 or more in Catalonia (Spain). 
Dataset dimension reduction. 
The initial dataset was composed on 31st December, 2012, of a registered active diagnosis with 
a certain prevalence value, out of 60 possible diseases for the 𝑁=916,619 patients included in the 
study. Additionally, considering age and the gender, each patient was initially characterized by a 
vector of 62 features, most of which were binary variables indicating the presence/absence of a 
disease at the end of 2012. For most of the study, diseases with prevalence ≥2% were filtered, 
resulting in 47 diseases and the corresponding 49 features (adding age and gender). Since most 
of the selected features were categorical instead of quantitative, the dataset was a mixture of 
numerical and categorical variables. We processed this dataset by applying a mixture of the well-
known Principal Component Analysis (PCA) to the numeric original features and a Multiple 
Correspondence Analysis (MCA) to the binary ones, in order to obtain a new dataset of reduced 
dimension. We selected the PCAmix algorithm, as described by Chavent et al, to perform the 
dimensionality reduction. It follows the criterion based on concentrating most of the variability 
of the new transformed features, that is to say, variance of the data in the low-dimensional 
representation were maximized. The Karlis-Saporta-Spinaki rule was followed to select the first 
13 dimensions out of the 49 for the 2% prevalence filtering, according to the eigenvalues of the 
PCAmix and the number of features and individuals in the dataset. As a result, after the PCAmix 
transformation and the extraction of the optimal number of dimensions, the new dataset was 
composed of 𝑁=916,619 vectors of 𝑑 = 13 features each one. In the following we denote this 
new dataset as 𝓨 ≔ {𝒚1, 𝒚2, … , 𝒚𝑁} , denoting by 𝒚2 ∈ ℝ13  for 𝑛 = 1, … , 𝑁  the new vector 
representing patient 𝑛.  
Soft clustering algorithm 
Once the transformed dataset 𝓨 was computed, a soft clustering algorithm was applied to fuzzily 
distribute the population into a set of clusters, corresponding to the different multimorbidity 
patterns. In a traditional clustering procedure patients are grouped in an exclusive way, so that if 
a certain patient belongs to a definite cluster then s/he cannot be included in another one. In 
contrast, an overlapping clustering, such as the Fuzzy C Means (FCM) algorithm, uses fuzzy sets 
to cluster patients, so that each patient belongs to all clusters with different degrees of 
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membership. The choice between a hard or a soft clustering algorithm is traditionally made based 
on the application and the performance obtained. In our case, the use of the FCM algorithm 
presented performance results similar to those of the hard clustering algorithm Kmeans, but 
clinically more solid. It was, therefore, chosen as the most appropriate method for the description 
of the multimorbidity patterns.  
FCM was originally introduced by Bezdek and yields an unsupervised form of grouping in which 
individuals can belong to more than one cluster. To do so, they are associated with an appropriate 
set of  𝐾  membership values, where 𝐾  denotes the number of clusters. The parameters that 
determine the clustering process are a set of 𝐾 centroids 𝐕 = {𝒗1, … , 𝒗𝐾} where 𝑣𝑘 ∈ ℝ13 for  𝑘 = 1, … , 𝐾  and a set of membership factors 𝐔 = {𝑢𝑗𝑛; 𝑗 = 1, … , 𝐾; 𝑛 = 1, … , 𝑁}   with 0 ≤ 𝑢𝑗𝑛 ≤ 1. Factor 𝑢𝑗𝑛 indicates the degree to which individual 𝑛𝑡ℎ belongs to cluster  𝑗𝑡ℎ. Both 
centroids 𝐕  and membership factors 𝐔  are obtained by iteratively minimizing the objective 
function 𝐽𝑚(𝐔, 𝐕, 𝓨), which is the weighted sum of squared errors within clusters 𝐽𝑚(𝐔, 𝐕, 𝓨) = ∑ ∑ (𝑢𝑗𝑛)𝑚𝐾𝑗=1𝑁𝑛=1 ‖𝒚𝑛 − 𝒗𝑗‖2;      1 < 𝑚 < ∞ (1) 
Thus, the similarity between an individual and a cluster centroid is measured through the squared 
error between the vector associated with the patient and the centroid prototyping the cluster. The 
fuzziness weighting parameter 𝑚, is selected to adjust the blending of the different clusters and it 
is any real number greater than 1. High m values would produce a fuzzy set of clusters so that 
individuals would tend to be equally distributed across clusters, whereas lower ones would 
generate a non-overlapped set of clusters. The FCM method iteratively alternates between 
computing the centroids in 𝐕 as the average of the individual’s features in 𝓨 previously weighted 
by the correspondent membership factors and estimating the membership factors in 𝐔 in order to 
maximize the cost function 𝐽𝑚(𝐔, 𝐕, 𝓨)  given the updated centroids in 𝐕 . In our work, we 
randomly initialized the set of centroids 𝐕 and halted the iterative process when 𝐽𝑚(𝐔, 𝐕, 𝓨) < 𝜖, 
where 0 < 𝜖 ≪1. This procedure converges to a local minimum or saddle point of 𝐽𝑚(𝐔, 𝐕, 𝓨). 
Cluster stability validation. 
Stable clusters are required in order to characterize multimorbidity patterns, consequently we 
applied 100 FCM independent runs to the transformed dataset 𝓨 and averaged both the 
membership factors and the centroid vectors, after ordering the clusters in descending order in 
terms of the summation of memberships to clusters, measured as ∑ (𝑢𝑗𝑛)𝑚𝑁𝑛=1 . This is 
equivalent to selecting the centroid and membership factors associated with the cluster with 
more population in each run and averaging them. Then after removing the selected cluster from 
each set, the procedure is repeated until a final set of clusters, composed of the 𝐾 averaged 
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centroids and the corresponding averaged membership factors, is obtained. In this averaging 
process we previously verified the similarity between the averaged parameters by a heuristic 
inspection of some randomly selected run results  
Number of clusters and fuzziness parameter validation. 
Since clustering algorithms are unsupervised, machine-learning techniques, the model fitting the 
dataset is traditionally computed through cost functions that depend on both the dataset and the 
clustering parameters and are denoted as validation indices. We computed three different well-
known validation indices to obtain the optimal number of clusters 𝐾 and the optimal value of the 
fuzziness parameter 𝑚: the partition coefficient validation index whose cost function is maximum 
for the optimal model, the Xie-Beni, and the partition entropy validation indices whose cost 
functions are minimum for the optimal models. A cross-validation technique was applied using a 
split sample approach, by randomly dividing the individuals into two different datasets, a first 
(50%) training dataset used for obtaining the averaged FCM clusters, and a second (50%) test 
dataset used to verify the model fitting the data.  
This validation procedure was applied to the set of clusters obtained after the previously explained 
averaging process, with the 2% prevalence filtering and considering 49 features before PCAmix 
reduction. We checked 𝑚 = 1.1, 1.2, and 1.5  and  𝐾 = 5, . . ,20 . In Figure1 the performance 
obtained through the three validation indices is depicted. The best behaviour is obtained for m=1.1 
and as is shown in Figure 2 and Figure 3 we can conclude that the optimal number of clusters for 
m=1.1 ranges from 6 to 12, validated with both the training dataset and the test dataset (more 
details are given in figures).  
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B) Computation of the observed/expected ratio and the exclusivity ratio. 
The observed/expected (𝑂/𝐸)𝑑𝑗 ratio and the exclusivity ratio 𝐸𝑋𝑑𝑗 have been used in this work 
in order to decide whether a disease 𝑑 is overrepresented or not in any given cluster 𝑗.  
The (𝑂/𝐸)𝑑𝑗 ratio was calculated by dividing disease prevalence in the cluster 𝑂𝑑𝑗 by disease 
prevalence in the overall population 𝐸𝑑 . As membership of an individual 𝑛 in a cluster 𝑗 was 
denoted by a membership degree factor 𝑢𝑛𝑗, and not as a binary variable, the observed disease 
prevalence 𝑂𝑑𝑗  in a cluster 𝑗  was computed as the ratio between the summation of the 
membership degree factors corresponding to all individuals suffering the disease 𝑑  and the 
summation of all the membership degree factors corresponding to the cluster 𝑗. Let us assume that 
there are 𝑛𝑑 individuals suffering the disease 𝑑 and that they are grouped in the set 𝐼𝑑, then the 
observed prevalence was computed as 
𝑂𝑑𝑗 = ∑ 𝑢𝑛𝑗𝑛∈𝐼𝑑∑ 𝑢𝑛𝑗𝑁𝑛=1  
while the expected prevalence was computed as  𝐸𝑑 = 𝑛𝑑𝑁  
Exclusivity ratio 𝐸𝑋𝑑𝑗, defined as the proportion of individuals with the disease 𝑑 included in the 
cluster 𝑗 over the total number of individuals with the disease 𝑛𝑑, was computed as  
𝐸𝑋𝑑𝑗 = ∑ 𝑢𝑛𝑗𝑛∈𝐼𝑑𝑛𝑑  
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Figure 1. Selection of the optimal m parameter 
Index m = 1.5 was also computed for Xie-Beni indices, but not included in the graph because the 
curve is significantly higher than the other two in the plot. 
Optimum Xie-Beni and partition entropy indices are at the minimum, whereas optimal choice for 
partition coefficient is at the maximum. For this reason, all plots are showing that m = 1.1 is the 
best parameter to optimize all the computed indices.   
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Figure 2. Selection of the optimal number of clusters (m = 1.1) 
Optimum Xie-Beni and partition entropy indices are at the minimum, whereas optimal choice for 
partition coefficient is at the maximum. Within the plots above, optimal values are located in the 
range from 6 to 12 clusters.   
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Figure 3. Cross-validation of the clustering with m = 1.1 
Optimum Xie-Beni and partition entropy indices are at the minimum, whereas optimal choice for 
partition coefficient is at the maximum. In the plots above we can find the optimal values in the 
range from 6 to 12 clusters. Additionally, no significant variation is registered in the indices 
regardless of the dataset selection.      
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Table 1. Variables characterizing each cluster in baseline study for 1% prevalence cut-off point (N= 916 619)  
 
        
 
 
1.Nervous and 
digestive 
2. Respiratory, 
circulator and 
nervous 
3. Circulatory and 
digestive 
4. Mental, nervous 
and digestive, 
female dominant 
5. Mental, 
digestive and 
blood, female 
oldest-old 
dominant 
6. Nervous, 
musculoskeletal 
and circulatory, 
female dominant 
7. Genitourinary, 
mental and 
musculoskeletal, 
male dominant 
8. Non-
specified, 
youngest-old 
dominant  
 
All 
 
Number of people, n  
25 142 46 144 64 299 86 819 113 910 154 411 178 511 247 382 916 619 
Multimorbidity, n (%) 25 011 (99.5) 45 969 (99.6) 64 210 (99.9) 86 815 (100.0) 113 869 (100.0) 154 406 (100.0) 177 392 (99.4) 185 414 (75.0) 853 085 (93.1) 
Polypharmacy, n (%) 16 859 (67.1) 33 629 (72.9) 49 776 (77.4) 64 969 (74.8) 76 376 (67.0) 96 657 (62.6) 94 463 (52.9) 54 773 (22.1) 487 502 (53.1) 
Women, n (%) 14 637 (58.2) 26 113 (56.6) 38 930 (60.5) 61 441 (70.8) 95 491 (83.8) 135 476 (87.7) 4 675 (2.6) 152 368 (61.6) 
 529 131 (57.7)  
Men, n (%) 10 506 (41.8) 20 031 (43.4) 25 369 (39.5) 25 378 (29.2) 18 419 (16.2) 18 935 (12.3) 173 836 (97.4) 95 014 (38.4) 
 387 488 (42.3)  
Age (categories), n (%) 
[65,70) 4 766 (19.0) 8 485 (18.4) 8 980 (14.0) 18 070 (20.8) 23 078 (20.3) 35 167 (22.8) 53 918 (30.2) 99 715 (40.3) 
 252 178 (27.5)  
[70,80) 10 562 (42.0) 19 970 (43.3) 24 698 (38.4) 34 460 (39.7) 43 362 (38.1) 72 030 (46.6) 86 357 (48.4) 103 146 (41.7) 
 394 586 (43.0)  
[80,90) 8 367 (33.3) 15 458 (33.5) 25 810 (40.1) 29 261 (33.7) 39 382 (34.6) 41 966 (27.2) 35 304 (19.8) 39 197 (15.8) 
 234 744 (25.6)  
[90,99] 1 448 (5.8) 2 230 (4.8) 4 811 (7.5) 5 028 (5.8) 8 089 (7.1) 5 248 (3.4) 2 933 (1.6) 5 324 (2.2) 
 35 111 (3.8)   
MEDEA* index  
R 
4 921 (19.6) 8 815 (19.1) 12 845 (20.0) 16 718 (19.3) 22 224 (19.5) 29 369 (19.0) 35 849 (20.1) 51 507 (20.8) 
 182249 (21.4)  
U1 
3 669 (14.6) 6 651 (14.4) 9 244 (14.4) 13 108 (15.1) 17 669 (15.5) 21 028 (13.6) 26 416 (14.8) 47 006 (19.0) 
 144791 (17.0)  
U2 
3 513 (14.0) 6 502 (14.1) 8 859 (13.8) 12 527 (14.4) 16 843 (14.8) 22 642 (14.7) 26 697 (15.0) 38 847 (15.7) 
 136431 (16.0)  
U3 3 624 (14.4) 6 806 (14.7) 9 057 (14.1) 12 495 (14.4) 16 973 (14.9) 24 536 (15.9) 27 619 (15.5) 37 112 (15.0) 
 138222 (16.2)  
U4 
3 452 (13.7) 6 586 (14.3) 8 808 (13.7) 12 279 (14.1) 16 327 (14.3) 24 859 (16.1) 27 294 (15.3) 33 383 (13.5) 
 132988 (15.6)  
U5 3 206 (12.8) 6 188 (13.4) 8 305 (12.9) 11 362 (13.1) 14 676 (12.9) 23 003 (14.9) 23 650 (13.2) 26 493 (10.7) 
 116883 (13.7)  
Number of chronic 
diseases, median [IQR] 
8.0 [6.0; 10.0] 8.0 [6.0; 10.0] 8.0 [6.0; 10.0] 8.0 [6.0; 10.0] 7.0 [5.0; 9.0] 6.0 [5.0; 8.0] 5.0 [4.0; 7.0] 3.0 [1.0; 4.0] 
6.0 [4.0;8.0]   
Number of chronic diseases (categories), n (%) 
0 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 25 380 (10.3) 
 25 380 (2.8)   
1 
131 (0.5) 175 (0.4) 90 (0.1) 5 (0.0) 41 (0.0) 5 (0.0) 1 120 (0.6) 36 588 (14.8) 
 38 154 (4.2)   
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[ 2, 5) 3 207 (12.8) 5 466 (11.8) 5 560 (8.6) 6 424 (7.4) 13 367 (11.7) 18 862 (12.2) 57 441 (32.2) 158 509 (64.1) 
 268 836 (29.3)  
[ 5,10) 14 285 (56.8) 27 482 (59.6) 37 649 (58.6) 54 013 (62.2) 78 670 (69.1) 116 135 (75.2) 109 238 (61.2) 26 237 (10.6) 
 463 709 (50.6)  
    ≥10 7 520 (29.9) 13 021 (28.2) 21 000 (32.7) 26 377 (30.4) 21 832 (19.2) 19 409 (12.6) 10 713 (6.0) 668 (0.3) 
 120 540 (13.2)  
Number of drugs, 
median [IQR] 
6.0 [4.0; 9.0] 7.0 [4.0; 10.0] 7.0 [5.0; 10.0] 7.0 [4.0; 10.0] 6.0 [4.0; 9.0] 6.0 [3.0; 8.0] 5.0 [3.0; 7.0] 2.0 [0.0; 4.0] 
 5.0 [2.0;8.0]   
Number of drugs (categories) 
0 
1 988 (7.9) 2 733 (5.9) 3 420 (5.3) 4 605 (5.3) 6 936 (6.1) 8 160 (5.3) 13 098 (7.3) 72 427 (29.3) 
 113 368 (12.4)  
1 
965 (3.8) 1 256 (2.7) 1 268 (2.0) 1 913 (2.2) 3 633 (3.2) 6 072 (3.9) 11 575 (6.5) 30 400 (12.3) 
 57 082 (6.2)   
[ 2, 5) 5 330 (21.2) 8 526 (18.5) 9 835 (15.3) 15 332 (17.7) 26 965 (23.7) 43 522 (28.2) 59 374 (33.3) 89 782 (36.3) 
 258 667 (28.2)  
[ 5,10) 11 033 (43.9) 21 308 (46.2) 30 250 (47.0) 42 078 (48.5) 56 341 (49.5) 75 147 (48.7) 76 377 (42.8) 50 148 (20.3) 
 362 681 (39.6)  
    ≥10 5 826 (23.2) 12 321 (26.7) 19 525 (30.4) 22 891 (26.4) 20 036 (17.6) 21 510 (13.9) 18 086 (10.1) 4 625 (1.9) 
 124 821 (13.6)  
Number of visits 2012, 
median [IQR] 
13.0 [7.0; 23.0] 13.0 [7.0; 21.0] 15.0 [8.0; 26.0] 14.0 [7.0; 24.0] 11.0 [6.0; 18.0] 11.0 [7.0; 17.0] 10.0 [6.0; 15.0] 5.0 [2.0; 9.0] 
 9.0 [5.0;16.0]  
Number of visits 2012 (categories), n (%) 
0 
667 (2.7) 983 (2.1) 1 212 (1.9) 1 727 (2.0) 2 563 (2.3) 2 459 (1.6) 3 916 (2.2) 34 418 (13.9) 
 47 945 (5.2)   
1 
550 (2.2) 887 (1.9) 1 070 (1.7) 1 536 (1.8) 2 342 (2.1) 2 282 (1.5) 4 671 (2.6) 20 546 (8.3) 
 33 884 (3.7)   
[ 2,  5) 2 389 (9.5) 4 242 (9.2) 5 030 (7.8) 7 700 (8.9) 12 166 (10.7) 14 734 (9.5) 24 789 (13.9) 59 389 (24.0) 
 130 439 (14.2)  
[ 5, 10) 5 390 (21.4) 10 384 (22.5) 12 356 (19.2) 18 483 (21.3) 29 941 (26.3) 43 668 (28.3) 55 517 (31.1) 73 610 (29.8) 
 249 349 (27.2)  
    ≥10 16 146 (64.2) 29 647 (64.3) 44 631 (69.4) 57 373 (66.1) 66 898 (58.7) 91 267 (59.1) 89 618 (50.2) 59 420 (24.0) 
 455 002 (49.6)  
For the sake of simplicity, all numbers in the table were rounded to its closest natural number  
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Table 2. Variables characterizing each cluster in baseline study for no prevalence cut-off point (N= 916 619)  
 
        
 
 
1.Nervous and 
digestive 
2. Respiratory, 
circulator and 
nervous 
3. Circulatory and 
digestive 
4. Mental, nervous 
and digestive, 
female dominant 
5. Mental, 
digestive and 
blood, female 
oldest-old 
dominant 
6. Nervous, 
musculoskeletal 
and circulatory, 
female dominant 
7. Genitourinary, 
mental and 
musculoskeletal, 
male dominant 
8. Non-
specified, 
youngest-old 
dominant  
 
All 
 
Number of people, n  
34 609 56 724 70 178 87 885 108 469 155 860 170 170 232 723 916 619 
Multimorbidity, n (%) 34 446 (99.5) 56 618 (99.8) 70 069 (99.8) 87 773 (99.9) 108 415 (100.0) 155 823 (100.0) 168 285 (98.9) 171 654 (73.8) 853 085 (93.1) 
Polypharmacy, n (%) 24 747 (71.5) 42 025 (74.1) 52 458 (74.8) 62 327 (70.9) 72 520 (66.9) 95 673 (61.4) 87 676 (51.5) 52 074 (22.4) 487 502 (53.1) 
Women, n (%) 17 458 (50.4) 31 444 (55.4) 42 390 (60.4) 66 619 (75.8) 91 266 (84.1) 129 678 (83.2) 6 227 (3.7) 144 047 (61.9) 
 529 131 (57.7)  
Men, n (%) 17 151 (49.6) 25 280 (44.6) 27 788 (39.6) 21 266 (24.2) 17 203 (15.9) 26 182 (16.8) 163 943 (96.3) 88 676 (38.1) 
 387 488 (42.3)  
Age (categories), n (%) 
[65,70) 6 968 (20.1) 9 731 (17.2) 10 239 (14.6) 17 869 (20.3) 25 715 (23.7) 36 946 (23.7) 51 412 (30.2) 92 307 (39.7) 
 252 178 (27.5)  
[70,80) 15 290 (44.2) 23 241 (41.0) 26 372 (37.6) 33 246 (37.8) 44 982 (41.5) 72 562 (46.6) 81 920 (48.1) 96 693 (41.5) 
 394 586 (43.0)  
[80,90) 10 875 (31.4) 20 373 (35.9) 27 952 (39.8) 30 488 (34.7) 32 319 (29.8) 41 430 (26.6) 33 959 (20.0) 38 357 (16.5) 
 234 744 (25.6)  
[90,99] 1 476 (4.3) 3 379 (6.0) 5 615 (8.0) 6 282 (7.1) 5 454 (5.0) 4 922 (3.2) 2 878 (1.7) 5 367 (2.3) 
 35 111 (3.8)   
MEDEA* index  
R 
7 199 (20.8) 12 283 (21.7) 16 063 (22.9) 19 200 (21.8) 21 807 (20.1) 32 218 (20.7) 36 483 (21.4) 50 996 (21.9) 
 182249 (21.4)  
U1 
5 502 (15.9) 9 073 (16.0) 11 462 (16.3) 15 001 (17.1) 17 925 (16.5) 22 513 (14.4) 27 114 (15.9) 47 040 (20.2) 
 144791 (17.0)  
U2 
5 445 (15.7) 8 862 (15.6) 10 921 (15.6) 14 028 (16.0) 17 500 (16.1) 24 185 (15.5) 27 171 (16.0) 38 667 (16.6) 
 136431 (16.0)  
U3 5 642 (16.3) 9 051 (16.0) 11 105 (15.8) 14 065 (16.0) 17 848 (16.5) 26 174 (16.8) 28 023 (16.5) 36 842 (15.8) 
 138222 (16.2)  
U4 
5 550 (16.0) 8 930 (15.7) 10 702 (15.2) 13 452 (15.3) 17 525 (16.2) 26 424 (17.0) 27 581 (16.2) 33 017 (14.2) 
 132988 (15.6)  
U5 5 272 (15.2) 8 525 (15.0) 9 926 (14.1) 12 139 (13.8) 15 864 (14.6) 24 346 (15.6) 23 798 (14.0) 26 161 (11.2) 
 116883 (13.7)  
Number of chronic 
diseases, median [IQR] 
8.0 [6.0; 10.0] 8.0 [6.0; 10.0] 8.0 [6.0; 10.0] 7.0 [6.0; 10.0] 7.0 [6.0; 9.0] 6.0 [5.0; 8.0] 5.0 [4.0; 7.0] 3.0 [1.0; 4.0] 
6.0 [4.0;8.0]   
Number of chronic diseases (categories), n (%) 
0 
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 340 (0.2) 24 718 (10.6) 
 25 380 (2.8)   
1 
150 (0.4) 140 (0.2) 144 (0.2) 104 (0.1) 46 (0.0) 61 (0.0) 1 747 (1.0) 35 302 (15.2) 
 38 154 (4.2)   
[ 2, 5) 4 022 (11.6) 5 351 (9.4) 7 343 (10.5) 9 477 (10.8) 10 628 (9.8) 27 127 (17.4) 58 129 (34.2) 144 766 (62.2) 
 268 836 (29.3)  
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[ 5,10) 20 440 (59.1) 32 996 (58.2) 41 917 (59.7) 56 331 (64.1) 74 196 (68.4) 112 073 (71.9) 100 295 (58.9) 26 838 (11.5) 
 463 709 (50.6)  
    ≥10 9 997 (28.9) 18 237 (32.2) 20 774 (29.6) 21 973 (25.0) 23 599 (21.8) 16 600 (10.7) 9 659 (5.7) 1 099 (0.5) 
 120 540 (13.2)  
Number of drugs, 
median [IQR] 
7.0 [4.0; 10.0] 7.0 [4.0; 10.0] 7.0 [4.0; 10.0] 7.0 [4.0; 9.0] 6.0 [4.0; 9.0] 5.0 [3.0; 8.0] 5.0 [3.0; 7.0] 2.0 [0.0; 4.0] 
 5.0 [2.0;8.0]   
Number of drugs (categories) 
0 2 174 (6.3) 3 310 (5.8) 4 049 (5.8) 5 328 (6.1) 6 377 (5.9) 8 768 (5.6) 13 693 (8.0) 68 920 (29.6) 
 113 368 (12.4)  
1 
1 052 (3.0) 1 508 (2.7) 1 665 (2.4) 2 406 (2.7) 3 600 (3.3) 6 433 (4.1) 11 557 (6.8) 28 489 (12.2) 
 57 082 (6.2)   
[ 2, 5) 6 636 (19.2) 9 880 (17.4) 12 006 (17.1) 17 824 (20.3) 25 972 (23.9) 44 986 (28.9) 57 244 (33.6) 83 239 (35.8) 
 258 667 (28.2)  
[ 5,10) 15 840 (45.8) 26 051 (45.9) 32 957 (47.0) 42 480 (48.3) 52 995 (48.9) 74 918 (48.1) 71 115 (41.8) 47 190 (20.3) 
 362 681 (39.6)  
    ≥10 8 908 (25.7) 15 974 (28.2) 19 502 (27.8) 19 847 (22.6) 19 525 (18.0) 20 755 (13.3) 16 561 (9.7) 4 885 (2.1) 
 124 821 (13.6)  
Number of visits 2012, 
median [IQR] 
13.0 [7.0; 22.0] 14.0 [8.0; 25.0] 14.0 [8.0; 25.0] 12.0 [7.0; 21.0] 11.0 [7.0; 18.0] 11.0 [7.0; 17.0] 9.0 [5.0; 15.0] 5.0 [2.0; 9.0] 
 9.0 [5.0;16.0]  
Number of visits 2012 (categories), n (%) 
0 766 (2.2) 1 122 (2.0) 1 435 (2.0) 2 027 (2.3) 2 274 (2.1) 2 771 (1.8) 4 278 (2.5) 32 903 (14.1) 
 47 945 (5.2)   
1 
675 (1.9) 959 (1.7) 1 302 (1.9) 1 871 (2.1) 2 089 (1.9) 2 572 (1.7) 4 798 (2.8) 19 408 (8.3) 
 33 884 (3.7)   
[ 2,  5) 3 171 (9.2) 4 578 (8.1) 6 024 (8.6) 8 987 (10.2) 11 289 (10.4) 15 678 (10.1) 24 339 (14.3) 55 804 (24.0) 
 130 439 (14.2)  
[ 5, 10) 7 708 (22.3) 11 373 (20.1) 14 299 (20.4) 20 681 (23.5) 28 386 (26.2) 44 934 (28.8) 52 979 (31.1) 68 497 (29.4)  249 349 (27.2)  
    ≥10 22 289 (64.4) 38 692 (68.2) 47 118 (67.1) 54 320 (61.8) 64 431 (59.4) 89 904 (57.7) 83 776 (49.2) 56 110 (24.1) 
 455 002 (49.6)  
For the sake of simplicity, all numbers in the table were rounded to its closest natural number  
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